• Type 2 diabetes mellitus (T2DM).

• Aged 50-75 years (inclusive), male or female.

• Early symptomatic dementia (Mild cognitive impairment or mild dementia), defined as:

‣ MMSE score \>20 and \<27,

⁃ CDR global score 0.5-1.0 (inclusive), with a CDR memory subscore ≥0.5,

⁃ Subjective memory complaints for ≥6 months.

• Stable glycemic control regimen for ≥3 months prior to screening, meeting one of the following:

‣ Lifestyle/dietary intervention alone (no glucose-lowering drugs),

⁃ Oral antidiabetic drugs (OADs), with or without once-daily basal insulin.

• HbA1c 7.0-9.0% (inclusive) at screening.

• BMI ≥20 kg/m², with stable weight (fluctuation \<5%) for ≥3 months.

• Stable treatment regimen for cognitive impairment for at least 3 months prior to screening and commit to its continuation throughout the study period, meeting one of the following criteria:

‣ No treatment: Not receiving any pharmacological or non-pharmacological interventions for cognitive impairment;

⁃ Non-pharmacological therapy only: Engaged exclusively in non-drug interventions (e.g., cognitive training);

⁃ Pharmacological therapy: Using approved symptomatic cognitive-enhancing medications (e.g., cholinesterase inhibitors, NMDA receptor antagonists), excluding disease-modifying therapies for Alzheimer's disease (AD).

• Ability to comply with systematic cognitive and functional assessments.

• Fully understands the trial protocol, voluntarily signs the informed consent form (ICF), and agrees to adhere to all study requirements and restrictions.